Impact of additional cytogenetic aberrations at diagnosis on prognosis of CML: long-term observation of 1151 patients from the randomized CML Study IVFABARIUS, Alice; LEITNER, Armin; JUNG-MUNKWITZ, Susanne et al.Blood. 2011, Vol 118, Num 26, pp 6760-6768, issn 0006-4971, 9 p.Article

Molecular mechanisms associated with leukemic transformation of MPL-mutant myeloproliferative neoplasmsBEER, Philip A; ORTMANN, Christina A; GREEN, Anthony R et al.Haematologica (Roma). 2010, Vol 95, Num 12, pp 2153-2156, issn 0390-6078, 4 p.Article

Inactivation of polycomb repressive complex 2 components in myeloproliferative and myelodysplastic/myeloproliferative neoplasmsSCORE, Joannah; HIDALGO-CURTIS, Claire; CHASE, Andrew et al.Blood. 2012, Vol 119, Num 5, pp 1208-1213, issn 0006-4971, 6 p.Article

Deep Molecular Response Is Reached by the Majority of Patients Treated With Imatinib, Predicts Survival, and Is Achieved More Quickly by Optimized High-Dose Imatinib: Results From the Randomized CML-Study IVHEHLMANN, Rüdiger; MÜLLER, Martin C; SCHNITTGER, Susanne et al.Journal of clinical oncology. 2014, Vol 32, Num 5, pp 415-423, issn 0732-183X, 9 p.Article

Myeloproliferative Neoplasm (MPN) Symptom Assessment Form Total Symptom Score: Prospective International Assessment of an Abbreviated Symptom Burden Scoring System Among Patients With MPNsEMANUEL, Robyn M; DUECK, Amylou C; FUENTES, Ana Kerguelen et al.Journal of clinical oncology. 2012, Vol 30, Num 33, pp 4098-4103, issn 0732-183X, 6 p.Article

JAK2V617F homozygosity arises commonly and recurrently in PV and ET, but PV is characterized by expansion of a dominant homozygous subcloneGODFREY, Anna L; CHEN, Edwin; BIJOU, Fontanet et al.Blood. 2012, Vol 120, Num 13, pp 2704-2707, issn 0006-4971, 4 p.Article

High-resolution single-nucleotide polymorphism array-profiling in myeloproliferative neoplasms identifies novel genomic aberrationsSTEGELMANN, Frank; BULLINGER, Lars; GRIESSHAMMER, Martin et al.Haematologica (Roma). 2010, Vol 95, Num 4, pp 666-669, issn 0390-6078, 4 p.Article